ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025
Impact of pretreatment PET/MRI on radiooncologic target delineation in Hodgkin's lymphoma: a case series.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePositron-emission tomography combined with computed tomography (PET/CT) is the diagnostic standard for patients with Hodgkin's lymphoma. Positron-emission tomography combined with magnetic resonance imaging (PET/MRI) is an alternative diagnostic modality that reduces radiation exposure to the patient. This study aims to evaluate the potential merits of PET/MRI compared to PET/CT for target delineation for radiotherapy of Hodgkin's lymphoma.
methodsFive patients with newly diagnosed Hodgkin's lymphoma underwent PET/CT imaging directly followed by PET/MRI imaging as part of initial staging. Both modalities were subsequently compared regarding each patient's diagnosed involved nodal regions. Three of these patients received radiotherapy after the completion of chemotherapy. In the radiotherapy planning CT, different gross tumor volumes and clinical target volumes were contoured for both PET/CT and PET/MRI and quantitatively compared using the Dice coefficient.
resultsNo differences regarding the diagnosed disease stage were observed. The delineated tumor and target volumes showed minor differences without clinical significance.
conclusionPositron-emission tomography/MRI is a viable option to assure adequate staging and later target delineation in patients with Hodgkin's lymphoma. Due to the reduction of radiation exposure compared to PET/CT, it might be the preferable option if readily available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.